C-Y9UACambridge Epigenetix
6-base genome, multiomics, epigenetic sequencing
research tools
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-Y9UA
C-Y9UAC-Y9UA6-base genome, multiomics, epigenetic sequencing
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer | News | News & insights | Syncona Content Search Navigation Sitemap About View this section View this section Who we are NAV Growth Framework Our people View this section View this section Board of Directors Portfolio View this section View this section Portfolio data Commercial companies Overview Autolus Therapeutics Late-stage clinical companies Overview Beacon Therapeutics Spur Therapeutics Clinical companies Overview iOnctura Resolution Therapeutics Anaveon Quell Therapeutics Mosaic Therapeutics Purespring Therapeutics … this section View this section Our approach to sustainability reporting Syncona Fellowship Sustainability policies The Foundation News & insights View this section View this section News Insights & articles Publications & presentations Investors View this section View this section Results and presentations RNS and inside information Share price centre Governance Our Committees Financial calendar Events calendar Analysts and advisers Shareholder information Overvie … this section View this section Our approach to sustainability reporting Syncona Fellowship Sustainability policies The Foundation News & insights View this section View this section News Insights & articles Publications & presentations Investors View this section View this section Results and presentations RNS and inside information Share price centre Governance Our Committees Financial calendar Events calendar Analysts and advisers Shareholder information Overvie
22 techbio soonicorns ready to cross the $1bn threshold | Sifted Analysis February 22, 2024 22 techbio soonicorns ready to cross the $1bn threshold The science-based startups primed for unicorn status Sadia Nowshin 5 min read Share Like pretty much every other tech sector, Europe’s techbio companies raised less in 2023 than the year before thanks to the economic downturn, bringing in $2.7bn compared to 2022’s $3.5bn, according to Dealroom. But investors are still excited about the potential for this sector, and the year saw some hefty rounds. Germany’s ITM Radiopharma, which develops and manuf … r, with investors like Sofinnova Partners, Andera Partners and Novartis Venture Fund on board. Quercis Pharma HQ : Switzerland Launched : 2019 Valuation : $600-900m Quercis Pharma is developing a drug to reduce the chance of high-risk cancer patients developing dangerous complications during treatment, like pulmonary embolisms and blood clots. It’s only ever raised one round — a $150m lump of funding in 2021 — from Global Emerging Markets. VectorY Therapeutics HQ : Netherland … ovable and how startups can partner with the tech giant News EIF launches €15bn fund of funds to back 100 growth-stage VCs Sadia Nowshin Sadia Nowshin was a reporter at Sifted covering foodtech, biotech and startup life. Follow her on X and LinkedIn # Biotech # Deeptech Deeptech & AI Mon The people, companies and trends shaping European AI and deeptech. Sign up for free Recommended Pro Frontier computing mapped: 70+ companies racing to power the AI era The startups that c … consumer to competitor Oshin Narang Pro 100+ companies the €5bn Scaleup Europe Fund could back We've been asking investors which companies they think the fund will back Freya Pratty , Anne Sraders and Federico Scolari From chargers to code: Europe’s EV infrastructure pivot EV charging is evolving from a network of physical charging points to a software-driven energy platform Sponsored by: AMP IT Company About Careers Advertising Cookie Policy Privacy Policy AI Code of C
Life science business accelerator Start Codon launches in Cambridge Home Categories Pharmaceutical Hi Tech Manufacturing Food Finance Company News Design & Build Containment Cleaning Sustainability HVAC Personal Protection Regulatory CT CONFERENCE Events Directory Search Close search Subscribe Login Password Password Remember me Forgot password? Close login form Cleanroom Technology Home Research & Development Life science business accelerator Start Codon launches in Cambridge Life science business accelerator Start Codon launches in Cambridge Published: 23-Apr-2019 Research & Deve … Research & Development Finance Early-stage startup companies are invited to apply for up to £250k in funding Keystone investors including Cambridge Innovation Capital, Babraham Bioscience Technologies, Roche's Genentech, Dr Jonathan Milner and Dr Ian Tomlinson are backing the launch of Start Codon, a new strategic initiative aimed at driving the translation of world-class research into commercially successful companies. Start Codon will identify and recruit high potential … the field of process-oriented, realistic and tailor-made training as well as application-specific support in GMP questions – was present again this year at the LOUNGES – Cleanroom Processes event. Bouygues completes $5.9bn acquisition of Equans The acquisition aims to strengthen the Group's construction business and will create a new business segment comprised of Equans and Bouygues’ Energies & Services arm will generate around $16.5bn in yearly sales Vishay Inter
BioCentury - New CEOs at Anjarium, Cambridge Epigenetix This Edition ARTICLE | Management Tracks New CEOs at Anjarium, Cambridge Epigenetix Plus Sema4’s CFO to step down, and updates from Marengo, Avilar, City of Hope and more By Gunjan Ohri, Data Content Analyst June 16, 2022 12:01 AM UTC Non -viral gene therapy company Anjarium Biosciences AG named Stephen Yoo CEO. Yoo was CMO and head of R&D at Third Harmonic Bio Inc., before which he was CMO at RegenxBio Inc. (NASDAQ:RGNX). Peter Fromen will become CEO at Cambridge Epigenetix Ltd. on July 18, replacing acting CEO Gail Marcus, who will
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Companies - Third Point Ventures This website uses cookies to ensure you get the best experience. I Agree Set only essential cookies Skip Navigation Third Point Logo Open Menu Approach Companies Team Currents Contact Championing World Changers. We do more than invest. We guide, coach, and connect our companies so they can get down to the business of making a difference. Here are their stories. Companies Filters Sectors Consumer Crypto Cybersecurity Data/AI/Analytics DevOps Fintech Healthcare Industrial IT Infrastructure Media Gaming and Metaverse Mobility Software (Enterprise/Applications) Thi … ign up for our newsletter Receive the latest news and updates from Third Point. Submit Contact 2180 Sand Hill Road Suite 210 Menlo Park, CA 94025 Phone: 650.433.5900 [email protected] Resources Jobs © 2022 Third Point LLC. All Rights Reserved. Privacy Policy Terms of Use Cookie Policy
Cambridge Epigenetix Ltd. - BioCentury Company Profiles - BCIQ About BioCentury Privacy & Legal Contact About BioCentury Company Overview Management Editorial & Research Scientific Advisory Board Privacy & Legal User Agreement Terms of Use Privacy Policy Use of Images & Market Data Reprints & Permissions Contact Contact Us Advertising & Sponsorship Customer Resource Center Career Opportunities Forgot Password © 2026 BioCentury Inc. All Rights Reserved. Copyright © 2026 BioCentury Inc. All Rights Reserved.
Jennifer L. Stone, PhD | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resources Documentation
J... - Cambridge University Venture Capital and Private Equity Facebook Log In Cambridge University Venture Capital and Private Equity's Post Cambridge University Venture Capital and Private Equity December 29, 2022 · Shared with Public Jason Mellad – Start Codon CEO and JEDI Jason is Start Codon's Co-Founder and CEO and is responsible for developing and implementing its strategy, managing and dealing with investor relations and working closely with Start Codon's portfolio companies to set and monitor their progress and to help them secure further investment and non-dilutive fin … tual property portfolio and fostered new spinouts. Jason was awarded a Marshall Scholarship to obtain his PhD in Medicine from Clare College, the University of Cambridge, focusing on vascular biology. He has a BSc (Summa Cum Laude) in Molecular Biology and Chemistry from Tulane University. Submit your application using this form: https://lnkd.in/eqRXGWDy *Please note that you can only access your form if you are signed in google from your . cam.ac.uk address (not jbs/or other
Somu Subramaniam - Director at Cambridge Epigenetix | The Org Platform Enrich Pricing Log in Sign up Cambridge Epigenetix Somu Subramaniam Unverified Somu Subramaniam Director Contact Somu is the Co-Founder and Managing Partner of New Science Ventures. Somu serves on the Board of Directors of Achronix Semiconductor Corporation, Alexar Therapeutics, Ario Pharmaceuticals, Dali Wireless, Dezima Pharma, Juventas Therapeutics, Oxyrane, Resolve Therapeutics, Svelte Medical Systems, TigerText, Vaultive, and iCAD. Som has also served on the Boards of Ception (acquired by Cephalon<), BioVex (acqui
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
GV - Tom Hulme home About Team Portfolio News Social Menu AI MODE Tom Hulme Managing Partner Tom Hulme Managing Partner Social X LinkedIn Investments Autolus * Biomodal Blockchain Blue Vision Labs * Carmera * Currencycloud * Genesis GoCardless * Gravity Sketch Lapse Lemonade * Monzo Multiverse Nothing Scandit Simply Snyk Stripe Tessl Vaccitech * nPlan Q.ai * * Denotes exit Tom Hulme’s eclectic career mirrors his broad range of interests: he worked as a teacher in a rural Muslim school in Tanzania, studied physics at university, founded an engineering startup, manufactured performance automobil … ol and an MBA from Harvard Business School, where he received the Baker Scholar Award of high distinction. He also received an honorary doctorate in Design from the University of the Arts London. Featuring Tom Apple’s second biggest acquisition ever is an AI company that listens to ‘silent speech’ The Verge 01/29/26 GV Bets Big On ‘AI Magic’ — Even When It Competes With Alphabet Crunchbase News 07/30/25 Tom Hulme on TBPN TBPN 03/19/26 Why Alphabet’s VC arm has doubled down on
Shankar Balasubramanian is thinking beyond DNA’s four-letter code --> Advertisement Skip to main content ACS ACS Publications C&EN CAS Jobs Main menu News Topics Newsletter Podcasts Explore Explore Skip Explore section Features Perspectives Interviews ACS News Graphics Chempics Games Newscripts Webinars Whitepapers & E-books Highlights Highlights Skip Highlights section How biochemistry fuels World Cup athletes Meet Jasmine Clark, the self-described ‘mad scientist’ running for the US House Australia’s $1.4 billion PFAS lawsuit could be a global model The road to sustainable rare earths … n Mistry ▸ Favorite place to be when not at home: Somewhere with warm sunshine, rolling hills, and vineyards ▸ Ambition not yet fulfilled: Climb a mountain above 6,000 m or play football for Liverpool FC. “Either option would do it!” ▸ The secret to running a successful research group: “Find the right balance between providing clear guidance and allowing room for exploration, [and] celebrate the efforts, achievements, and successes of everyone.” What were the biggest challeng … appeared in ACS Central Science : cenm.ag/shankar . Send the reporter feedback Submit a Letter to the Editor for publication Chemical & Engineering News ISSN 0009-2347 Copyright © 2026 American Chemical Society Enjoyed the article? Share Shankar Balasubramanian is thinking beyond DNA’s four-letter code Coinventor of next-generation sequencing has widened his focus to DNA’s large-scale structures and molecular modifications cen.acs.org Advertisement More in Genomics Edito
Our Companies - New Science Ventures Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent. Accept close Home About Us News Our Companies Our Team Contact Us Investor Portal close Our Companies We focus on sectors that have strong decades-long tailwinds, where we have direct experience and where we can leverage our strong external networks to cr
Industry News | One Nucleus Skip to main content Sign-up Log in Main navigation Events Events Overview ON Helix Genesis Annual Awards Industry Events One Nucleus Events Membership Membership Overview Member Benefits Membership Prices Member Directory Sponsorship Services Services Overview Savings Savings Overview Purchasing Scheme Event Savings Training Training Overview Upcoming Courses Training Sat Nav Mentoring Student & Post Doc Membership Facilities Management Facilities Management Overview Facilities Management Lab Space Equipment for Sale About Company Bio Our Team Our Board Publica … ies of carbohydrate-… Read more 22 November 2021 2021 Astellas Future Innovator Prize at We Are Pioneer Group Are you building an innovative and emerging life science or biotechstart-up?Now is your opportunity to accelerate your research and transform it into meaningful value for patients byapplying for an Astellas Future Innovator Prize.Astellas is o ering up to two Future Innovator Prizes for a pioneering science and technology platformthat would be a game-changing approach … Biology, Genetic Regulation, Immuno-Oncology, Cell Therapy, and other areas The award for each Astellas Future Innovator Prize winner will:Cover the… Read more 18 November 2021 PharmaVentures and Shinhan Investment Corp sign Memorandum of Understanding to strengthen global collaboration for the Korean biopharma industry OXFORD, England, Nov. 18, 2021 /PRNewswire/ -- PharmaVentures is delighted to announce it has signed a Memorandum of Understanding (MOU) with the leading Kore
Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Reso
Cambridge Epigenetix advances funding sequence with $21m - Global Venturing Global Venturing | Cambridge Epigenetix advances funding sequence with $21m Where Global Innovation and Capital Meet Home --> Register Login Go Corporate University Impact Full Site Corporate University Impact Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resol
BIOMODAL LAUNCHES SOLUTION TO SIMULTANEOUSLY SEQUENCE GENETICS AND EPIGENETICS IN ONE WORKFLOW Accessibility Statement Skip Navigation Resources Investor Relations Journalists +44 (0)20 7454 5110 Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All Public Company News All Multimedia News View All News Releases Regulatory News D/A/CH Regulatory New … Nature Biotechnology Prof. Dennis Yuk Ming Lo, recent Lasker-DeBakey Award recipient and liquid biopsy pioneer, joins biomodal's Scientific Advisory Board Omead Ostadan, genomics industry veteran and former Illumina and Seer executive, joins biomodal Board of Directors CAMBRIDGE, England , April 13, 2023 /PRNewswire/ -- The duet multiomics solution is the world's first single-base-resolution sequencing technology that enables the simultaneous ph … ng Kong (CUHK), and winner of the 2022 Lasker-DeBakey Clinical Medical Research Award, joins the Scientific Advisory Board (SAB). Prof. Lo brings decades of research experience to the SAB, having personally played an important role in the development of trailblazing diagnostic strategies, particularly in non-invasive prenatal testing for multiple diseases. Prof. Lo has pioneered a number of approaches to cancer liquid biopsy, especially for the detection of nasopharyngeal car … ces Blog Journalists Data Privacy Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Customer Portal Resources Blog Journalists +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookie Settings Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company. --> --
Cambridge Epigenetix – Funding, Valuation, Investors, News Dashboard VC firms Startups Pricing News Newsletter About API Terms of Service | © 2019-2026 Parsers, Inc [email protected] Bonus program Sign Up - 10 credits = $1 Terms of Service | ©2024 Parsers, Inc [email protected] --> Add company Sign up Log In Edit Cambridge Epigenetix http://www.cambridge-epigenetix.com/ Last activity: 03.11.2021 Active Categories: Analytics Chemicals Development Diagnostics HealthTech Human Platform Provider Science Tools Cambridge Epigenetix has a vision to improve healthcare through routine measurement of
Jobs at biomodal | Sequoia Capital You are using an outdated browser. Please upgrade your browser to improve your experience and security. OUR FOUNDERS OUR COMPANIES OUR TEAM COMPANY DESIGN STORIES Our Founders Our Companies Our team Company Design stories Powered by Consider Privacy Terms ABOUT Our Ethos Our History FAQ Jobs Newsletter Legal BUSINESS ENTITIES U.S./Europe India Southest Asia China Heritage SCGE LOGIN LP Login Sequoia Ampersand Login © 2021 Sequoia
Cambridge Epigenetix raises $21M, poaches new CEO from Illumina - MedCity News Twitter Facebook TikTok YouTube LinkedIn RSS Subscribe via email Newsletter Signup Send Tips Webinars eBooks Open navigation MedCity News Toggle Search Close navigation News Health Tech BioPharma Devices & Diagnostics Consumer / Employer Contributors MedCity Influencers Events Bullseye INVEST Digital Health Podcasts Research Newsletters Newsletter Signup Send Tips Webinars eBooks Twitter Facebook TikTok YouTube LinkedIn RSS Subscribe via email Search for: Search Startups, BioPharma Cambridge Epigenetix raises $2
biomodal Files Patent Infringement Lawsuit Against Watchmaker Genomics | FirstWord HEALTHTECH You need to enable JavaScript to run this app. Loading...
Member profile: biomodal | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company BioStart: for early-stage entrepreneurs Search sector opportunit … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association Member profile: biomodal biomodal Lab Supplies/Services Cambridge Phone +44 (0)12 2380 0700 Website https://biomodal.co
Privacy policy | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resources Documentation, litera … (in writing, by telephone or by email/text message), to respond to any query or application which you send via our website; to engage with third-parties where we have engaged them to deliver services that have been requested. These may include references, qualifications, criminal reference checking services. to provide you with information about our organisation and/or our career opportunities; to produce aggregated data analytics, statistical research and reports, which may … cit consent to the processing of the personal data contained within your online application. For further information, see the separate Privacy Policy relating to Greenhouse . Data protection legislation provides you with certain rights in relation to this processing (see below: ‘Your Rights’) – you can, for instance, withdraw your consent to the processing of this personal data at any time. However, this is likely to mean that you will not be able to continue with your applic … al data in order to comply with any legal obligation, or in order to enforce or apply our website terms of use and other agreements or otherwise for the purpose of legal advice and/or proceedings; or to protect the rights, property, or safety of biomodal, our customers, or others. How is your personal data protected? Your personal data is only shared with staff within our organisation and with any partners who work closely with us on a ‘need to know’ basis for our legitimate … to require us to erase personal data held by us about you. This right will only apply where (for example): we no longer need to use the personal data to achieve the purpose we collected it for; or where you withdraw your consent if we are using your personal data based on your consent; or where you object to the way we process your data (in line
Ahren Leads $30mn Funding Round in Cambridge Epigenetix - Ahren Innovation Capital We are now investing from our latest fund and have over $400M in dry powder Home Team Companies About News Connect Ahren Leads $30mn Funding Round in Cambridge Epigenetix 2 April, 2018 Ahren has led the successful $30MN Series C funding round for Cambridge Epigenetix (“CEGX”) with strong participation from existing investors. CEGX is a pioneer in the development and application of epigenetic technologies and aims to change the way medicine is practiced by reducing several routine and important diagnostic screeni … o keep pushing scientific boundaries.” About Ahren LP Ahren LP is an investment fund that supports transformational companies at the cutting edge of deep science and deep tech. The technologies of its Founding Partners are today valued in excess of $100BN combined. A group of highly diverse, creative and original thinkers leading their domains, Ahren believes in taking considered risk that will deliver superior rewards – capturing a generational opportunity to provide smart c … AIMER This press release does not constitute an offer of interests in any Ahren fund. Any offer of an Ahren fund will be made through separate offering documents and in accordance with applicable laws and regulations. This press release may contain forward looking statements. These statements include, but are not limited to, discussions related to Ahren’s expectations regarding the performance of its business, its liquidity and capital resources and the other statements … dication of the current or future performance of the portfolio companies of the fund that Ahren manages. Further Reading 24 September, 2024 News Constructive Bio Secures $58 Million in Series A Financing 17 April, 2024 News Mentee Robotics Unveils MenteeBot: a humanoid robot that integrates AI across all operational layers 3 August, 2023 News Adrestia Acquired by Insmed Incorporated, Bringing its Novel Approach to Tackling Intractable Genetic Diseases to Insmed’s Early-Stage … Classes of Enzymes, Pharmaceuticals and Biomaterials prev page Ahren Announces Fund Launch – a New Approach for a New Investment Era next page Animal-free Cheese Brand, New Culture, Closes Their $25m Series A Investment Click here to sign up and stay in touch Home Team Companies About News Connect Copyright © 2017 - 2025 Ahren Innovation Capital
Robert Osborne, PhD | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resources Documentation, l … arly in his career, Robert worked with pioneering molecular biologist and Nobel Prize recipient, Dr. Sydney Brenner to secure the first patents for Unique Molecular Identifiers. He has a PhD in Genetics from the University of Nottingham and was a Postdoctoral Fellow at the University of Rochester, NY, and a Postdoctoral Research Associate at the University of Oxford. Robert is the inventor or co-inventor of 19 patents and author of more than 20 scientific publications includi
Cambridge Epigenetix lands $21M to boost epigenomics research + | Bioworld | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GL
BIOMODAL LAUNCHES SOLUTION TO SIMULTANEOUSLY SEQUENCE GENETICS AND EPIGENETICS IN ONE WORKFLOW Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Phot … rticle in Nature Biotechnology Prof. Dennis Yuk Ming Lo , recent Lasker-DeBakey Award recipient and liquid biopsy pioneer, joins biomodal's Scientific Advisory Board Omead Ostadan, genomics industry veteran and former Illumina and Seer executive, joins biomodal Board of Directors CAMBRIDGE, England , April 13, 2023 /PRNewswire/ -- The duet multiomics solution is the world's first single-base-resolution sequencing technology that enables the simultaneous phased reading of gene … ng Kong (CUHK), and winner of the 2022 Lasker-DeBakey Clinical Medical Research Award, joins the Scientific Advisory Board (SAB). Prof. Lo brings decades of research experience to the SAB, having personally played an important role in the development of trailblazing diagnostic strategies, particularly in non-invasive prenatal testing for multiple diseases. Prof. Lo has pioneered a number of approaches to cancer liquid biopsy, especially for the detection of nasopharyngeal car … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
The next Cambridge game-changer: Epigenetix Skip to content Study at Cambridge About the University Research at Cambridge Services Connecting Cambridge Innovation Academic Consultancy Services Pioneering Research Innovations Venture Building & Investment About Who we are Our team Our performance Careers The Cambridge Ecosystem Beyond the University Partnerships and collaboration FAQs Stories Events Publications Contact Search Search Menu News The Cambridge game-changer for the next decade 02 December 2016 One of Cambridge Enterprise’s most exciting new portfolio companies is Cambridge Epi
A high-performance toolkit for large-scale analysis of 5- and 6-base genomes | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources … ency, making it a more practical choice for large-scale epigenomic analyses. 5. Application to a CRC dataset modality can process large cohorts of samples genome-wide on a standard laptop. Here we show an example of an analysis on a colorectal cancer dataset . We call DMRs between Control and Stage I patients on promoters (defined as 1kb upstream of TSS) of protein-coding genes from the GENCODE hg38 annotation database. We identify significant DMRs by filtering by q-value and
biomodal launches solution to simultaneously sequence genetics and epigenetics in one workflow | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid … rticle in Nature Biotechnology Prof. Dennis Yuk Ming Lo , recent Lasker-DeBakey Award recipient and liquid biopsy pioneer, joins biomodal’s Scientific Advisory Board Omead Ostadan , genomics industry veteran and former Illumina and Seer executive, joins biomodal Board of Directors The duet multiomics solution is the world’s first single-base-resolution sequencing technology that enables the simultaneous phased reading of genetic and epigenetic information in a single sa … ng Kong (CUHK), and winner of the 2022 Lasker-DeBakey Clinical Medical Research Award, joins the Scientific Advisory Board (SAB). Prof. Lo brings decades of research experience to the SAB, having personally played an important role in the development of trailblazing diagnostic strategies, particularly in non-invasive prenatal testing for multiple diseases. Prof. Lo has pioneered a number of approaches to cancer liquid biopsy, especially for the detection of nasopharyngeal car
Zymo Research Announces Strategic Partnership with biomodal to Deliver Next-Gen Multiomic Insights Erklärung zur Barrierefreiheit Navigation überspringen Zurück zu Global Sites +44 (0)20 7454 5110 DSGVO Journalisten Weitere Informationen anfordern Nachrichten Produkte Kontakt Hamburger menu Weitere Informationen anfordern Telefon +44 (0)20 7454 5110 von 8 AM - 5 PM GMT Kontakt Kontakt +44 (0)20 7454 5110 von 8 AM - 5 PM GMT --> Weitere Informationen anfordern Journalisten DSGVO --> Weitere Informationen anfordern Journalisten DSGVO Weitere Informationen anfordern Journalisten DSGVO Weitere Inf … Großbritannien Vereinigte Staaten Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Globale Seiten Asien Brasilien Kanada Tschechische Republik Dänemark Finnland Frankreich Deutschland Indien Israel Italien Mexiko Naher Osten Niederlande Norwegen Polen Portugal Russland Slowakei Spanien Schweden Großbritannien Vereinigte Staaten +44 (0)20 7454 5110 von 8 AM - 5 PM GMT Terms of Use Privacy Policy Informa
Biomodal Limited Sponsor Licence Check | Sponsor Licence Checker UK Sponsor Licence Checker UK sponsor search Sponsors Cities Industries Visa Routes Blog Find Jobs ← Back to Directory Biomodal Limited Saffron Walden SIC 72110 Sponsor Profile Summary Biomodal Limited is listed in the UK sponsor register with Saffron Walden as its sponsor location and Skilled Worker as its listed route. The company profile is categorised as SIC 72110. Companies House lists the matched company number as 08005377. Companies House shows the company status as active. The company type is ltd. The matched company reco … g. Useful for skilled worker research 10 min Read guide Company Research How to Apply to UK Sponsor Companies and Get More Replies A practical application and outreach guide for candidates who need UK Skilled Worker sponsorship. Useful for skilled worker research 8 min Read guide Want to work here? Search for open roles at Biomodal Limited on our dedicated job platform. Search Jobs on GradSponsor Sponsor Licence Checker UK sponsor search The most comprehensive directory of UK
Biomodal | Investment Portfolio | JIMCO® Who We Are Who We Are Our People Strength in Heritage Principled profits: What ESG means for private investors Read more The sky’s the limit Read more What We Do Portfolio Funds Life Sciences Fund Strategic Asset Fund Technology Fund Principled profits: What ESG means for private investors Read more The sky’s the limit Read more News & Media Press Releases In the News Insights & Features Principled profits: What ESG means for private investors Read more The sky’s the limit Read more The Jameel Philanthropies Bab Rizq Jameel Art Jameel Community … mpany, JIMCO, is the global investment arm of the Jameel Family. STATUS Current FUND Life Sciences Biomodal Biomodal (previously Cambridge Epigenetix ) is a life sciences tools and analytics company, founded in 2012, by Professor Sir Shankar Balasubramanian FRS and Dr. Bobby Yerramilli-Rao. Biomodal is seeking to revolutionize genome sequencing through a proprietary technology platform that has the potential to deliver step changes in both the type of information that can be … upported by their extensive IP portfolio. In late 2021, the JIMCO Life Sciences Fund participated in biomodal’s US$ 88 million Series D funding round (previously Cambridge Epigenetix). Series D Extension Nov 2021 FOUNDING TEAM Prof. Sir Shankar Balasubramanian FRS Co-Founder and Director Dr. Bobby Yerramilli-Rao Co-Founder and Director FOUNDED 2012 website Easily integrating into existing sequencers, the company’s products allow the user to see at-a-glance genomic and e … traction platform. Read more Sign up to our newsletter Language English العربية Submit I confirm that I am over 18 years of age, or over the legal age of majority in my country of residence. I consent to having this website store my submitted information to respond to my inquiry. Abdul Latif Jameel Investment Management Company, JIMCO, is the global investment arm of the Jameel Family. Universal Navigation Terms of Use Cookie Policy Accessibility Policy Privacy Policy Copyrig
duet data interpretation guide — Data Interpretation Guide 1.5.0 Skip to main content Back to top Ctrl + K duet data interpretation guide Search Ctrl + K Download PDF Search Ctrl + K duet data interpretation guide Download PDF duet data interpretation guide duet data interpretation guide # This documentation is compatible with duet pipeline version 1.5.x Introduction The biomodal duet multiomics solution bioinformatics pipeline is a bioinformatics tool used for analysing genetic and epigenetic information present in a sample. It can be used with both double-stranded genomic DNA and cell-
Cambridge Epigenetix Raises $88 Million Series D Financing to Advance Best-in-Class DNA Sequencing Technology Platform | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing P
biomodal - Company Profile Boring Business Nerd Daily Stories Interviews Resources Startup Jobs Angel Investors VC Firms About subscribe Home > Startups Database > biomodal biomodal Using epigenetics to reduce several diagnostic tests for common cancers to a simple blood draw. About Founded 2012 Headquarters Cambridge, England, United Kingdom Industry Biotech Company Description biomodal is an omics based life-sciences technology and analytics company delivering products that bring the dynamism of our ever-changing biology into focus. Our duet multiomics solution enables more epigenetic
biomodal Careers 2026: 10 Interview Questions + Jobs Scoutify FEATURES PRICING COMPANIES BLOG ABOUT Scoutify SIGN IN TRY IT FREE Enterprise SaaS biomodal is hiring. 1 roles open right now. Scoutify monitors biomodal's career page directly and notifies you within minutes when a new role goes live, hours before it hits LinkedIn or Indeed. GET BIOMODAL ALERTS HQ United States Posted (30d) 0 Home / Companies / biomodal INTERVIEW PREP 10 interview question s for biomodal See 10 interview questions [ 01 ] HIRING NOW Live from their career page. Numbers refresh daily. Every role tracked here was … to biomodal and 10,000+ other companies while you focus on interview prep. Auto-apply from $15/week, cancel anytime. SIGN UP FREE [ 04 ] IN THEIR OWN WORDS How biomodal pitches itself. “ Reveal the power of the 6‑base genome ” Explore multiple modes of biology from a single sample in a single experiment Capture genetic and epigenetic information simultaneously in a single workflow to better understand normal and disease biology. Source: biomodal.com [ 05 ] VISA SPONSORSHIP U. … h Park, Cambridge, ENG CB10 1XL, so you know where you'd report before you apply. Office data © OpenStreetMap contributors [ 07 ] ABOUT What biomodal does, and who fits. Biomodal delivers advanced solutions for understanding complex biology through multiomics. Biomodal is an omics-based life sciences technology and analytics company focused on developing products that illuminate the dynamic interplay of genomics and epigenomics. Our solutions, including duet +modC and du … y Account Manager position, it may be worthwhile to inquire directly during the application process. What is the average salary and compensation structure at biomodal? What is the interview process like at biomodal? What is the company culture like at biomodal? Does biomodal offer remote work or a hybrid policy? What is the current hiring volume and what roles are open right now at biomodal? Who leads biomodal and how stable is the company? What opportunities for career growt … s the company? What opportunities for career growth does biomodal offer? PREP + APPLY Done prepping? Let Scoutify apply for you. Auto-apply to jobs at biomodal and thousands more. Your applications keep flowing while you prepare. BROWSE FREE Browse the board free without an account. Real-time alerts from $5/week, auto-apply from $15. Product REAL
biomodal's duet multiomics solution technology | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Reso
A biomodal distribution of plasma HVA/MHPG in the psychoses A biomodal distribution of plasma HVA/MHPG in the psychoses Psychiatry Res . 1997 Mar 24;69(2-3):97-103. doi: 10.1016/s0165-1781(96)03061-2. Authors S E Ottong 1 , D L Garver Affiliation 1 Department of Psychiatry, Southwestern Medical Center, University of Texas, Dallas, USA. PMID: 9109177 DOI: 10.1016/s0165-1781(96)03061-2 Abstract In an attempt to estimate dopamine production in psychotic patients, pHVA and pMHPG were assessed from morning blood samples of fasting, neuroleptic-free patients. The (pHVA/pMHPG) ratio was
Does Biomodal Limited Sponsor UK Visas? - 2026 Check UK Sponsor List Data from GOV.UK Sponsors Cities Industries Guides Getting Sponsored Visa Routes Certificate of Sponsorship Licence Status Eligibility & Salary Avoid Scams Free Resources Tier 2 Sponsor List GOV.UK Sponsor List Sponsorship Checker Recent Changes ← Back to Checker Does Biomodal Limited Sponsor UK Visas? Visa Sponsorship Status YES Biomodal Limited is a licensed sponsor on the official GOV.UK register. Licence Details Visa Route Rating Location — Want to contact them? View the full company profile to see website, LinkedIn, and
biomodal's duet multiomics solution technology | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Reso
Sponsors | CSHL Meetings And Courses About Us Events Newsstand Partner With Us Careers Giving Education Programs Faculty Research Banbury Center CSHL Press DNA Learning Center Meetings & Courses Ph.D. Program Meetings & Courses Program Crossroads of Biology Meetings & Courses Program Crossroads of Biology Meetings & Courses Program Crossroads of Biology Meetings & Courses Program Crossroads of Biology Previous Next Home Meetings Courses Home Meetings Courses Welcome Info Register Travel Abstracts Sponsors Payments Policies 2026 Meetings Program Sponsorship Corporate Sponsor … in the sciences. Check individual meeting web pages for details on how to apply for these awards. Federal support may be restricted to U.S. citizens, permanent residents or individuals working in U.S. labs. In general, requests for financial aid should be made by email to the individual administrator listed on the meeting web page. Aid is awarded on the basis of funding available at the meeting, the active participation of the person requesting support (i.e., submission … ravel support is rarely included unless it is a specific condition of a special award. Meetings & Courses Meetings & Courses Program Meetings Courses Sponsors Archives Privacy Participation Online Store Shop here Travel Getting Here Links CSH - Asia Program The Leading Strand Expert Chats Current Exchange Twitter CSHL Meetings Twitter CSHL Courses Instagram Contact Us Meetings & Courses Program Cold Spring Harbor Laboratory One Bungtown Road, Cold Spring Harbor, NY 11724 (516
Zymo Research | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resources Documentation, literat
| One Nucleus Skip to main content Sign-up Log in Main navigation Events Events Overview ON Helix Genesis Annual Awards Industry Events One Nucleus Events Membership Membership Overview Member Benefits Membership Prices Member Directory Sponsorship Services Services Overview Savings Savings Overview Purchasing Scheme Event Savings Training Training Overview Upcoming Courses Training Sat Nav Mentoring Student & Post Doc Membership Facilities Management Facilities Management Overview Facilities Management Lab Space Equipment for Sale About Company Bio Our Team Our Board Publications Media Ki
McGill University in Partnership with Lady Davis Institute - Lunch & Learn | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resource
biomodal at the Element Biosciences Aviti 24 Roadshow - Paris | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources
Zymo Research Announces Strategic Partnership with biomodal to Deliver Zymo Research Announces Strategic Partnership with biomodal to Deliver – Zymo Research Europe Modal × Cookies Verwalten Ihre Zufriedenheit steht für uns an erster Stelle. Daher setzen wir Cookies ein, um den sicheren und zuverlässigen Betrieb unserer Website zu gewährleisten, die Leistung zu analysieren und unsere Inhalte bestmöglich auf Sie abzustimmen. Cookies sind erforderlich, damit unsere Website technisch einwandfrei funktioniert und externe Inhalte angezeigt werden können. Außerdem erfassen wir beispielsw … Literature Scientific Posters Bisulfite Beginner Guide Certificate of Analysis Grant Programs Tools Student Resource Hub Subscription Center Quick Order Request a Quote Direct Ordering Options Find a Distributor OEM & Custom Manufacturing NGS Services Inquiry Special Offers Who We Are Advisory Board Press Releases Sustainability The Zymo Research Promise ISO Certification Careers Contact Us Products NGS Services Applications Automation Resources Ordering About Contact Sign u
Explore biology in every mode | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resources Docume
Careers | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resources Documentation, literature an
Co-Sponsored Chicago Multiomics Mixer | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resource … using one 5ng DNA sample Read more Attending from biomodal Carmen Guarco Field Application Scientist Jennifer L. Stone, PhD Vice President, Business Development and Customer Solutions Kurt Yardley Director of Global Marketing Mark Consugar Associate Director of Scientific Affairs Thao Huynh Scientific Affairs Partner Register now Meet our team at the event AACR Mixer 29APR25 140331857124 Stay up to date Explore recent biomodal news and the events that we’ll be attendin
Careers | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resources Documentation, literature an
biomodal News February 2026: Element partnership, evoC pub. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy P
biomodal launches Certified Service Provider program for duet multiomics 5-base and 6-base sequencing solutions | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precisio
biomodal and Element Biosciences Combine Duet Multiomic and High-Throughput Sequencing Capabilities to Advance Clinical Research | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative diseas
Jobs at biomodal | GV You are using an outdated browser. Please upgrade your browser to improve your experience and security. About Team Portfolio News Social Close AI Mode Close Linkedin Instagram Facebook Youtube X Request an AI Summary Gemini ChatGpt Claude Grok perplexity ` About Team Portfolio News Social Linkedin Instagram Facebook Youtube X AI Mode Request an AI Summary Powered by Consider Privacy Terms Linkedin Instagram Facebook Youtube X Privacy Policy News Press Jobs © 2026 GV. All rights reserved.
Explore biology in every mode | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resources Docume
Position | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resources Documentation, literature a
DEF 14A false 0001851194 DEF 14A 0001851194 ecd:NonPeoNeoMember ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember 2024-01-01 2024-12-31 0001851194 ecd:NonPeoNeoMember ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember 2023-01-01 2023-12-31 0001851194 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2024-01-01 2024-12-31 0001851194 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember 2023-01-01 2023-12-31 0001851194 ecd:NonPeoNeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2023-01-01 2023-12-31 0001851 … represented and voted at the annual meeting. Therefore, we urge you to vote and submit your proxy promptly via the Internet, telephone or mail. On behalf of our Board of Directors, we would like to express our appreciation for your continued support of and interest in Ventyx. Sincerely,     Raju Mohan, Ph.D. Chief Executive Officer, President and Director     Table of Contents VENTYX BIOSCIENCES, INC. 12790 El Camino Real, Suite 200 San Diego, California 9 … mportant . Whether or not you plan to attend the annual meeting, we urge you to submit your proxy or voting instructions via the Internet, telephone or mail as soon as possible.   By order of the Board of Directors,     Raju Mohan, Ph.D. Chief Executive Officer, President and Director San Diego, California April 23, 2025       Table of Contents   TABLE OF CONTENTS       Page QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND … d Code of Business Conduct and Ethics   14 Director Compensation   14 PROPOSAL NO. 1: ELECTION OF CLASS III DIRECTORS   17 Nominees   17 Vote Required   17 Board Recommendation   17 PROPOSAL NO. 2: ADVISORY VOTE ON EXECUTIVE COMPENSATION   18 Compensation Program and Philosophy   18 Vote Required   18 Board Recommendation   18 PROPOSAL NO. 3: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM   1 … s sent directly to you by us. As a stockholder of record, you have the right to grant your voting proxy directly to the individuals listed on the proxy card or to vote on your own behalf at the annual meeting. Throughout this proxy statement, we refer to these holders as “stockholders of record.” Street Name Stockholders . If your sha
Careers | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resources Documentation, literature an
Cancer Biology Jobs at biomodal | Consider You are using an outdated browser. Please upgrade your browser to improve your experience and security. Home Sign In Powered by Consider Privacy Terms
biomodal_Limited_et_al_v_Watchmaker_Genomics_Inc__codce-25-03646__0001.0.pdf PacerMonitor A Fitch Solutions Service Features Plans & Pricing About Home Features Pricing Getting Started About Us Start Free Trial Sign In Admin Login × START YOUR 14-DAY FREE TRIAL Confidential, secure access. Switch plans or cancel any time. We have this document in our database and it is free with your trial access. PLUS For small businesses and individuals USD 49 monthly ✔ Documents 15¢ / page ✔ 5 free custom alerts ✔ Full database access ✔ Free basic searching START FREE … IAL FREE FOR 14 DAYS * Monthly subscription waived during trial. Usage fees may apply. Privacy Policy • Cookie Policy • Terms • About PacerMonitor, LLC © 2026.
Europe Epigenetics Market Report 2025-2030, By Product & Service, Method, and Geo Home Biotechnology Europe Epigenetics Market Europe Epigenetics Market Size, Growth, Share & Trends Analysis Cybersecurity market by offering, solution type, services (professional and managed), deployment mode (on-premises cloud, and hybrid), organisation size (large enterprises and SMEs), security type, vertical and region-global forecast to 2028 --> Report Code BT 9846 Published in Jun, 2026, By MarketsandMarkets™ Fact checked Cite this Research --> Download PDF Request Customisation Speak to An … oftware], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology], End User - Forecast to 2030 --> Europe Epigenetics Market by Product & Service [Enzymes, Kits & Reagents (Antibodies), Software], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology], End User - Forecast to 2030 --> DESCRIPTION TABLE OF CONTENTS METHODOLOGY DOWNLOAD … oftware], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology], End User - Forecast to 2030 USD 1.22 BN MARKET SIZE, 2030 CAGR 14.1% (2025-2030) 320 REPORT PAGES 370 MARKET TABLES OVERVIEW Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis The Europe epigenetics market, valued at USD 0.57 billion in 2024, stood at USD 0.63 billion in 2025 and is projected to advance at a re … discovery and translational epigenomics. Europe epigenetics product market, By Application In 2024, oncology dominated the Europe epigenetics market, as epigenetic alterations are central to tumor biology, disease classification, and biomarker discovery. Methylation and chromatin signatures are widely used to support patient stratification, treatment response assessment, and resistance research in translational studies. The growing pipeline of targeted therapies and expandin … hnology : NGS PCR & qPCR Mass Spectrometry Sonication Other Technologies By Application : Oncology Metabolic Diseases Immunology Developmental Biology Cardiovascular Diseases Other Applications By End User for Product : Academic & Research Institutes Pharmaceutical & Biotechnology Companies Hospitals & Clinics Contract Research Or
Cambridge Epigenetix Raises $88 Million Series D Financing to Advance Best-in-Class DNA Sequencing Technology Platform | News | News & insights | Syncona Content Search Navigation Sitemap About View this section View this section Who we are NAV Growth Framework Our people View this section View this section Board of Directors Portfolio View this section View this section Portfolio data Commercial companies Overview Autolus Therapeutics Late-stage clinical companies Overview Beacon Therapeutics Spur Therapeutics Clinical companies Overview iOnctura Resolution Therapeutics Anaveon Quell Ther … this section View this section Our approach to sustainability reporting Syncona Fellowship Sustainability policies The Foundation News & insights View this section View this section News Insights & articles Publications & presentations Investors View this section View this section Results and presentations RNS and inside information Share price centre Governance Our Committees Financial calendar Events calendar Analysts and advisers Shareholder information Overvie … this section View this section Our approach to sustainability reporting Syncona Fellowship Sustainability policies The Foundation News & insights View this section View this section News Insights & articles Publications & presentations Investors View this section View this section Results and presentations RNS and inside information Share price centre Governance Our Committees Financial calendar Events calendar Analysts and advisers Shareholder information Overvie
(Opens in new tab) (Opens in new tab) (Opens in new tab) Login Join Free Fields & Topics Life Sciences All Content Applications & Methods News & Articles Videos Events & Summits Webinars Drug Discovery & Development Biopharmaceuticals Basic Research Target Discovery Lead Discovery Pre-Clinical Development Clinical Development Drug Manufacturing Clinical Diagnostics All Content Clinical CE Webinars CLINICAL24 Applications & Methods News & Articles Videos Events & Summits Webinars Immersive Content Environmental All Content Applications & Methods News & Ar … events Editorial Features Immersive Content Resources SelectScience eBooks All application eBooks Life Sciences Drug Discovery Clinical Diagnostics Environmental Materials Food & Beverage General Lab Lab Automation Lab Informatics Separations Spectroscopy Forensics Cannabis Testing How-to-Buy eBooks Applications & Methods All Applications & Methods Life Sciences Drug Discovery Clinical Diagnostics Environmental Materials Food & Beverage General Lab Lab Automa … events Editorial Features Immersive Content Resources SelectScience eBooks All application eBooks Life Sciences Drug Discovery Clinical Diagnostics Environmental Materials Food & Beverage General Lab Lab Automation Lab Informatics Separations Spectroscopy Forensics Cannabis Testing How-to-Buy eBooks Applications & Methods All Applications & Methods Life Sciences Drug Discovery Clinical Diagnostics Environmental Materials Food & Beverage General Lab Lab Automa
About biomodal | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resources Documentation, litera
Cambridge Epigenetix | Collaboration and Impact Skip to main content Study at Cambridge About the University Research at Cambridge Search site Yusuf Hamied Department of Chemistry Login Menu Collaboration and Impact Cambridge Epigenetix Our understanding of the role of the epigenome in disease has become a new weapon in the fight against cancer. Since DNA from cancer cells has a distinct epigenetic signature, a new technique developed by Professor Sir Shankar Balasubramanian and Professor Wolf Reik to detect the two most common epigenetic modifications at single-base resolution created the pos
biomodal: Getting more information from DNA – Cambridge Enterprise Skip to content Study at Cambridge About the University Research at Cambridge Services Connecting Cambridge Innovation Academic Consultancy Services Pioneering Research Innovations Venture Building & Investment About Who we are Our team Our performance Careers The Cambridge Ecosystem Beyond the University Partnerships and collaboration FAQs Stories Events Publications Contact Search Search Menu Case Studies biomodal: Getting more information from DNA 05 December 2024 Changing the story of cancer biomodal's multiomics
Cambridge Epigenetix raises $88 million Series D financing to advance best-in-class DNA sequencing technology platform - New Science Ventures Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent. Accept close Home About Us News Our Companies Our Team Contact Us Investor Portal close News Archive Antevia Networks secures JOSCAR Accreditation as
board Archives | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resources Documentation, litera
Balasubramanian Group - Cancer Research UK Cambridge Institute Research Themes Themes Artificial intelligence Cancer detection Cell biology Clinical integration Personalised medicine Tumour microenvironment Research Groups Research Groups Affiliated Clinical Faculty Publications Publications Facilities Core Facilities Work with our Core Facilities Virtual Tour Explore our 360° tour Careers & Study Build a purposeful career that makes a real difference Join us Vacancies Careers Working here Students News & Events The latest science and news from the Institute Find out more News Behind the Lab C … ations and G4 structures are located in the cancer cell genome, and through the application of synthetic small molecules that selectively target G4 structures, we aim to understand the oncogenic process and develop novel approaches for potential use in treatment and diagnosis of cancer. We are also exploring new strategies to target the DNA binding activity of FOXM1, a key cancer-related transcription factor involved in cell cycle control. Professor Sir Shankar Balasubramania … ted News See all news Shankar Balasubramanian receives the Princess of Asturias Award for Scientific and Technical Research 14th May 2026 The 2026 award recognises Prof Balasubramanian and his co-recipients David Klenerman and Pascal Meyer for their pioneering work in genome sequencing technologies. Find out more Prof Sir Shankar Balasubramanian Awarded Prestigious Royal Society of Chemistry Prize 25th June 2025 Professor Sir Shankar Balasubramanian has received the Royal Soc … Sir Shankar Balasubramanian has received the Royal Society of Chemistry Khorana Prize, awarded for outstanding contributions through work at the chemistry and life science interface. Read more Sir Shankar Balasubramanian elected Fellow of the AACR Academy 10th March 2025 Sir Shankar has been recognised for his pioneering research in nucleic acid chemistry and his key role in the development of next-generation sequencing technology. Find out more See all news Publications See
Prof. Sir Shankar Balasubramanian FRS | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resource … logy of cancer. His collective contributions span fundamental chemistry and its application to the biological and medical sciences. Sir Shankar was knighted in the Queen’s New Year’s Honours in 2017 for his services to science and medicine and awarded the Royal Society’s Royal Medal in 2018. In 2021, he was awarded the 2020 Millennium Technology Prize jointly with David Klenerman and the 2022 Breakthrough Prize for Life Sciences jointly with David Klenerman and Pascal Mayer f
Nuclear Dynamics and Cancer | Fox Chase Cancer Center - Philadelphia PA Skip to main content Utility Nav About Us Blog History Administrative Leaders Clinical Leaders Research Leaders External Advisory Board Administrative Offices Care Connect News & Publications Events International Partners Careers Locations Contact Us Giving Patient Portal Katz School of Medicine Utility Nav 2 Find a Doctor Request Appointment 888-369-2427 Main navigation Clinical Care About Fox Chase Cancer Center Cancer Types & Conditions Clinical Residencies and Fellowships Clinical Trials Departments Patient Sto … ting Read More Fox Chase Cancer Center Researcher Lu Chen Receives $250,000 NIH Grant to Further Investigation of RNA Read More Fox Chase Cancer Center Researchers Find Differences in the Gut Microbiomes of Bladder Cancer Patients Read More Fox Chase Cancer Center Researchers Find Gene That Triggers Immune Response in Treatment-Resistant Small-Cell Lung Cancer Read More Differentiation Therapy a Promising Treatment for Medulloblastoma, Fox Chase Cancer Center Researchers Show … Read More Fox Chase Cancer Center Researcher Yu ‘Sunny’ Liu, PhD, Receives NIH Grant to Study Genetic Links to Disease Read More Star Wars Against Cancer: Attacking the Clones — Novel Strategy Could Mean More Durable Treatment for Leukemia Read More Fox Chase Researcher Receives Grant to Explore How to Indirectly Target Signaling Protein in Pancreatic Cancer Read More Study Finds Novel Mechanism for Making Small Cell Lung Cancer Tumors Vulnerable to Attack by Immune System R … or Third Year in a Row With American Society of Hematology Abstract Achievement Award Read More Study Identifies Key Mutations That Make New DNA Repair Enzyme Inhibitors More Effective Read More Fox Chase Researcher Henkel Valentine Recognized as an IMPACT Fellow by the National Postdoctoral Association Read More Fox Chase Researcher Receives Grant for Study of RNA, Telomerase and Implications for Disease Read More Fox Chase Researcher Receives Department of Defense Grant to
%PDF-1.7 %���� 1 0 obj >/Metadata 7178 0 R/ViewerPreferences 7179 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 35 0 R 36 0 R 37 0 R 38 0 R 39 0 R] /MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��][o9�~���/ H�q�w�w�'Y���b&���Ŗmab�Ǒ3;�g��a/�n�������r��H�Ư��.�������y����v���_�4��]n���ÿ�}��q����j�خ6�w??��G 7����������߷oHK�?c4mH#;�r�Aێ5O˷o������Oo�HJ["�O�o��Ӥ��T� 7-3ͧ��_~���7���2����}�y����|���7 ����훃��g��j�w??.�0�_� y������-�g���nP���NeƤ���aP87���p}~��������?�sa … endobj 184 0 obj > endobj 7178 0 obj >stream Microsoft® Word for Microsoft 365 application/pdf Annabel Clark Microsoft® Word for Microsoft 365 2025-06-18T19:31:01+01:00 2025-06-19T07:05:46+01:00 2025-06-19T07:05:46+01:00 uuid:CAE17544-FC20-4CD8-9377-1C1E925D3730 uuid:16d30c2f-fa8a-2c48-b31b-4bd084507fac endstream endobj 7181 0 obj > endobj xref 0 2 0000000000 65535 f 0000986513 00000 n 184 1 0000986702 00000 n 7178 1 0000986904 00000 n 7181 1 0000990313 00000 n trailer ]/Pre
Cell-free whole genome and epigenome sequencing to detect and classify cancers from plasma circulating DNA skip to main content Funding Opportunities Funding Programs Policies, Guidelines & Templates Our Research Research Projects Marathon of Hope Cancer Centres Network Digital Health and Discovery Platform At a Glance About Cancer Updates News & Events Links E-Newsletters About Us About Us Terry Fox and the Terry Fox Foundation Terry Fox and Osteosarcoma Partners Our People Annual Financial Statements Annual Impact Report Careers Contact Terry Fox Research Institute Digital Health and Discove … rcher(s) Trevor Pugh Samuel Aparicio Duration August 01, 2024 to April 01, 2026 Award Value $350,000.00 A team of researchers in Ontario and BC is hoping to transform how we detect, diagnose and monitor cancer thanks to new funding from the Marathon of Hope Cancer Centres Network (MOHCCN) and the Terry Fox Research Institute. The team, which is led by Drs. Trevor Pugh (Princess Margaret Cancer Centre, University Health Network) and Samuel Aparicio (BC Cancer Research In … u can support our research! Your donation to the Terry Fox Foundation will help fund groundbreaking cancer research projects across Canada. Donate The Terry Fox Research Institute seeks to advance our understanding, diagnosis and treatment of cancer with the goal of improving significantly the outcomes of cancer research for the patient. TFRI supports research through a highly collaborative, team-oriented, milestone-based approach to attain this goal. Funding Opportunities Te
AACR Annual Meeting 2026 | Exhibitor Floor Plan Selected Exhibitor Search Results Available Booth Zoom In Zoom Out Max Fit Highlight Available Booths Display Booth Dimensions Orientation: Landscape Portrait Print Screenshot Include Booth Results: None Search Results Include Exhibitor Names on Floor Plan: Yes Print Hall(s): Current Hall All Halls Show Available Booths Your floor plan printout is processing. If you selected multiple halls it may take a minute for your print to finish. Loading... Creating Printout..... PRINT MY FLOOR PLAN
Brainwaves & Brews: A Co-Sponsored Neuroscience Multiomics Mixer | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Re
Cambridge Epigenetix Strengthens Leadership Team to Support Development of Epigenetics-Based Diagnostics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Cambridge Epigenetix Strengthens Leadership Team to Support Development of Epigenetics-Based Diagnostics November 2, 2017 | 3 min read Twitter LinkedIn Facebook Email Print Cambridge Epigenetix announced that it has appointed diagnostic experts, Hayden Jeffreys as Chief Operating Officer (COO … 2 November 2017 : Cambridge Epigenetix (CEGX), a pioneer in the development and application of epigenetic technologies, today announced that it has appointed diagnostic experts, Hayden Jeffreys as Chief Operating Officer (COO) and Dr Joanne Mason as Vice President (VP) of Biomarker Discovery. Following on from the appointment of Dr Vitali Proutski, Vice President Informatics, in June this year, these appointments further strengthen CEGX’s in-house expertise to help drive the … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cambridge Epigenetix announces programme for routine screening and detection of colorectal cancer and other common tumours - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busine … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Cambridge Epigenetix announces programme for routine screening and detection of colorectal cancer and other common tumours January 8, 2019 | 4 min read Twitter LinkedIn Facebook Email Print Company granted broad and exclusive patent rights for the use of an epigenetic biomarker as a diagnostic tool for cancer. CAMBRIDGE … -( BUSINESS WIRE )-- Cambridge Epigenetix Ltd, a pioneer in the development and application of epigenetic technologies, today announces its discovery and development programme for a test to detect colorectal and other cancers. This follows completion of a c. $30 million funding round, as well as the acquisition of exclusive patent rights for its epigenetic sequencing platform. Epigenetic changes act as a control layer for the genome and can alter gene expression, but not the … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cambridge Epigenetix And NuGEN Sign Partnership Agreement To Combine Leading Technologies In Epigenetics Research - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Cambridge Epigenetix And NuGEN Sign Partnership Agreement To Combine Leading Technologies In Epigenetics Research August 15, 2017 | 4 min read Twitter LinkedIn Facebook Email Print August 15, 2017 10:52 AM Eastern Daylight Time CAMBRIDGE, England--( BUSINESS WIRE )-- Cambridge Epigenetix (CEG … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
biomodal to Present New 6-Base Genome Data Showing Enhanced Sensitivity for Detection of Stage I Colorectal Cancer in Plasma cell-free DNA at American Society of Human Genetics Meeting 2024 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRI … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases biomodal to Present New 6-Base Genome Data Showing Enhanced Sensitivity for Detection of Stage I Colorectal Cancer in Plasma cell-free DNA at American Society of Human Genetics Meeting 2024 November 4, 2024 | 3 min read Twitter LinkedIn Facebook Email Print CAMBRIDGE, England--(BUSINESS WIRE)--biomodal, a … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
biomodal Files Patent Infringement Lawsuit Against New England Biolabs - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search biomodal Files Patent Infringement Lawsuit Against New England Biolabs July 2, 2024 | 2 min read Twitter LinkedIn Facebook Email Print CAMBRIDGE, England – July 2, 2024 – biomodal, an omics-based life sciences technology and analytics company, today announced it has filed a lawsuit against New England Biolabs (“NEB”) in … d we will act vigorously to protect our IP rights and our customers’ ability to apply differentiated solutions that deliver best-in-class results." biomodal’s growing patent portfolio currently includes more than 25 U.S. and over 40 internationally issued patents, with more than 75 patent applications pending worldwide. About biomodal biomodal is an omics-based life-sciences technology and analytics company delivering products that bring the dynamism of our ever-changing biol … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
biomodal Delivers the 6-Base Genome with a Powerful New Multiomic Solution, duet evoC - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search biomodal Delivers the 6-Base Genome with a Powerful New Multiomic Solution, duet evoC February 5, 2024 | 4 min read Twitter LinkedIn Facebook Email Print biomodal, an omics-based life sciences technology and analytics company, today announced it is delivering the 6-base genome to customers with the launch of duet multio … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
biomodal and Element Biosciences Combine Duet Multiomic and High-Throughput Sequencing Capabilities to Advance Clinical Research - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases biomodal and Element Biosciences Combine Duet Multiomic and High-Throughput Sequencing Capabilities to Advance Clinical Research February 23, 2026 | 3 min read Twitter LinkedIn Facebook Email Print CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--biomodal, an omics-based life sciences technology and a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BIOMODAL LAUNCHES SOLUTION TO SIMULTANEOUSLY SEQUENCE GENETICS AND EPIGENETICS IN ONE WORKFLOW - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BIOMODAL LAUNCHES SOLUTION TO SIMULTANEOUSLY SEQUENCE GENETICS AND EPIGENETICS IN ONE WORKFLOW April 13, 2023 | 6 min read Twitter LinkedIn Facebook Email Print biomodal (formerly known as Cambridge Epigenetix) commercially launches its new duet multiomics solution, revealing the combinatorial power of genetic and epige … rticle in Nature Biotechnology Prof. Dennis Yuk Ming Lo , recent Lasker-DeBakey Award recipient and liquid biopsy pioneer, joins biomodal's Scientific Advisory Board Omead Ostadan, genomics industry veteran and former Illumina and Seer executive, joins biomodal Board of Directors CAMBRIDGE, England , April 13, 2023 /PRNewswire/ -- The duet multiomics solution is the world's first single-base-resolution sequencing technology that enables the simultaneous phased reading of gene … ng Kong (CUHK), and winner of the 2022 Lasker-DeBakey Clinical Medical Research Award, joins the Scientific Advisory Board (SAB). Prof. Lo brings decades of research experience to the SAB, having personally played an important role in the development of trailblazing diagnostic strategies, particularly in non-invasive prenatal testing for multiple diseases. Prof. Lo has pioneered a number of approaches to cancer liquid biopsy, especially for the detection of nasopharyngeal car … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
biomodal Publishes Study in Nature Communications Medicine Highlighting Breakthrough in Earlier Colorectal Cancer Detection - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases biomodal Publishes Study in Nature Communications Medicine Highlighting Breakthrough in Earlier Colorectal Cancer Detection January 20, 2026 | 3 min read Twitter LinkedIn Facebook Email Print The company’s 6‑base sequencing solution integrates additional methylation signals, delivering an AUC of 0.95 for … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cambridge Epigenetix Establishes Scientific Advisory Board - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releas … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Cambridge Epigenetix Establishes Scientific Advisory Board March 6, 2017 | 3 min read Twitter LinkedIn Facebook Email Print Cambridge, UK, 6th March, 2017: Cambridge Epigenetix, a pioneer in the development and application of epigenetic technologies, today announces the formation of its Scien … mbridge Research Institute. His recent awards include the Royal Society Mullard Award (2009), The BBSRC Innovator of the year (2010) and the Tetrahedron Prize (2013). He is a Fellow of The Royal Society, The Academy of Medical Sciences and a member of EMBO. Wolf Reik, FRS FMedSci, who has been a scientific advisor since the company’s founding in 2012, is Head of the Epigenetics Programme at the Babraham Institute in Cambridge and its Associate Director. He is honorary Profess … iences at the University of Washington, where his lab's focus is to develop and apply new technologies in genomics and molecular biology, with an emphasis on next-generation DNA sequencing and its applications in human genetics. In addition to pioneering the application of liquid biopsies to identify the contributions of cancerous cells and foetal anomalies, Professor Shendure’s team at the University of Washington reported the first haplotype-resolved genome and epigenome of … d genome and epigenome of a human cancer. He is the recipient of the Curt Stern Award from the American Society of Human Genetics in 2012, the FederaPrijs from the Federation of Dutch Medical Scientific Societies in 2013, and a National Institutes of Health Director's Pioneer Award in 2013. Dr Jason Mellad, CEO at Cambridge Epigenetix, commented:
2024 Exhibitors | The Technical Vendor Association The Technical Vendor Association Bringing vendors and the research community together. Menu Skip to content Home About Mission Membership Career Contact NIH Exhibit FAQ 2024 Exhibitors Dates: September 24th and 25th! There are different exhibitors each day. Time: 10am-3pm Location: NIH Building 10 South Lobby and FAES Terrace FAES Link: https://faes.org/content/faes-classrooms-terrace App : find the Terrace or South Lobby: https://www.takemethere.cc.nih.gov/ If you are an NIH Scientist attending the event, please register here so we can
Case study | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resources Documentation, literature
Genome Science 2024 | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resources Documentation, l … odal insights into genome organisation and gene regulation Dan Brudzewsky Field Application Scientist biomodal 16 July, 1800-1930 & 17 July 12, 1300-1400 Poster presentation Find the venue One sample. One workflow. One solution. Here are the relevant biomodal resources for information. Find poster presentation information, case studies, interviews, and more. duet multiomics solution evoC product sheet Novel single-base-resolution solution that delivers the standard four-base
Fox Chase Cancer Center’s Cancer Epigenetics Institute to Present Data From Ongoing Collaboration at biomodal Workshop at AACR Annual Meeting | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegene
Exhibitor Spotlight Theaters - AACR Annual Meeting News MENU Home News Session Recaps Meeting Previews NextGen Stars Photos Industry Events Satellite Educational Symposia Exhibitor Spotlight Theaters Industry Content Featured Exhibitors Get News Updates Meeting Home Register Now MENU Get News Updates Meeting Home Register Now Exhibitor Spotlight Theaters Please Note: The Exhibitor Spotlight Theaters are promotional activities and are not approved for continuing education credit. The content of the Exhibitor Spotlight Theaters are the opinions of the presenters and do not represent the position
%PDF-1.5 %���� 57 0 obj > endobj 56 0 obj > endobj 58 0 obj > endobj 69 0 obj > stream x��} \�������{��, ��{9�� ����HB��@\�p�Ш�wQ���֫j[�5 @�G5�/���V�a���ڴ��j��f�;�B�MW�v���7כ�7o�0BȀ#�4�g�"p�����=c,�9����MJO��`-��!�ӻ�v_��X���S�ĵ�wp-�^ Y���P�qa�@�\�B7��4"� �Rj�T>,�����Ic�Z�z>�6t7����I�J��ͨ{( ��i�{i���s�~��)�1Ky���am?�����g��~=Bgn͢9t ��| �D�4���VK?&���S�@O��@C�A���|~x�!�Y9�4Mc�/���8)�b_E_ �M�-�m� ��=O�_�� �E�=�}l��7� ��ٮ�����9�N�s�����:��TU���� �f�I� }�/ �A�4#&�����N;+*��:�f�@�=�X+g�dCyO/ b����k&�96��� @�D�`���V��̈́�Ϡ�~��Lve�T9�[�:Hx9[��@y�o��K�cy( u�~�D
Boston Epigenetics Society - DNA: What is it trying to tell us? With biomodal founder Shankar Balasubramanian | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision